US ▾
NDSN
Earnings call · Jul 2026 (Q3 FY26)

NORDSON Q3 FY26 earnings call NDSN

Aug 20, 2026 Source

Executive summary

Nordson Q3 FY26 — Record Sales and EPS Driven by Strong Backlog and Growth End Markets

Nordson delivered a robust Q3 FY26, surpassing guidance with record sales and adjusted EPS, fueled by broad-based organic growth and accelerating order momentum across all segments. The company's Ascend Strategy and NBS Next framework continue to drive profitable growth, particularly in semiconductor, electronics, and medical end markets. Strong cash generation and a healthy balance sheet position Nordson for continued strategic capital deployment and future growth.

Highlights

5
  • Record sales of $818 million, a 10% increase year-over-year, with 12% organic growth.

  • Record adjusted EPS of $3.25, a 19% increase year-over-year, exceeding guidance.

  • Record EBITDA of $262 million, representing 32% of sales.

  • Free cash flow of $237 million, with a 144% conversion rate on net income.

  • Backlog increased 35% year-over-year, providing strong visibility into 2027.

Concerns

2
  • A $15 million noncash mark-to-market charge for minority investments impacted GAAP other expenses.

  • General inflationary pressures tied to broader market and geopolitical factors are being managed.

Guidance & targets

CategoryTargetConfidence
Full-year sales
$3.035 billion to $3.075 billion
high materiality
High
Full-year adjusted earnings per share
$11.80 to $12 per diluted share
high materiality
High
Full-year effective tax rate
near 18%
medium materiality
High
Long-term effective tax rate
18%
medium materiality
High
Long-term growth algorithm
half organic, half inorganic
high materiality
High
Advanced Technology Solutions (ATS) FY27 growth rate
mid-single-digit
high materiality
Medium

Segment performance

SegmentRevenueYoYQoQMargin
Industrial Precision Solutions
Organic growth driven by packaging, industrial coatings, and plastics processing demand. Aftermarket demand remains stable, while systems demand for broader industrial and agricultural markets remains stable with limited growth. EBITDA margin in line with prior year.
Organic sales growth: 3%
$367 million5%—35% of sales
Medical and Fluid Solutions
Record quarterly sales and EBITDA. Organic growth driven by engineered fluid solutions and medical product lines. Divested sales from medical contract manufacturing had a negative 6% impact. Medical component demand normalized, broad-based demand for fluid solution systems in medical and electronics markets.
Organic sales growth: 11%Prior year EBITDA: $83 millionEBITDA margin sequential improvement: 100 bps
$231 million5%—$88 million (38% of sales)
Advanced Technology Solutions
All-time quarterly record sales and EBITDA. Growth across Electronics Dispense and Test and Inspection product lines, reflecting continued strength in semiconductor and broadening electronics end market demand. Margin improvement reflects record sales volumes and strong operational leverage.
Organic sales growth: 31%Prior year EBITDA: $42 millionPrior year EBITDA margin: 24%
$220 million28%—$66 million (30% of sales)

Orderbook & backlog

Total backlog up 35% Q3 FY26

35% compared to prior year

Backlog growth was broad-based with all segments contributing, particular strength from Advanced Technology and Medical segments. Majority ships within about 6 months, taking orders into 2027.

Backlog turnover about 6 months Q3 FY26

The majority of backlog ships within about 6 months; 80% or so of backlog turns over within 6 months, with a few long lead time items.

Deals & partnerships

CapstanAG Small bolt-on acquisition

Completed during the second quarter of this year.

null Medical contract manufacturing business

Divestiture completed in the fourth quarter of last year.

Risks & headwinds

Noncash mark-to-market charge for minority investments Q3 FY26

$15 million

Mitigation:These noncash valuation adjustments are subject to market volatility, and on a year-to-date basis, the impact is actually negligible.

General inflationary pressures near-term

general inflationary pressures

Mitigation:managing and mitigating our way through while maximizing our growth potential

Geopolitical factors near-term

tied to the broader market and geopolitical factors

Mitigation:managing and mitigating our way through while maximizing our growth potential

What to watch in Q4 FY26

ATS growth rate

FY27
Current 30% organic growth in Q3 FY26
Target Mid-single-digit growth from all-time peak

Why it matters

To assess the sustainability of the semiconductor/electronics cycle and the segment's ability to grow off a high base.

As we head into next year, though, our expectation is we're going to build off of this peak, and we're going to build at a rate that is more in line with our longer-term mid-single-digit number.

Q&A highlights

Asked for context on the strong 35% backlog growth, including lead time elongation, visibility into next year, and historical comparisons.

Management stated backlog growth was broad-based across all segments, with no significant elongation in lead times. The majority of backlog turns over in about 6 months, providing visibility into 2027. On-time delivery has improved to 80-95%.

“Our backlog, generally speaking, turns over in about 6 months. The majority of our backlog ships within about 6 months. So clearly, as of the end of the third quarter, we're taking orders into 2027 at this point, but no elongation in lead times.”

asked by Michael Halloran · answered by Daniel Hopgood

3 min read 7 chapters

Detailed narrative

Ascend Strategy and NBS Next Framework Driving Performance

Nordson's strategic framework, NBS Next, is credited for driving strong operational execution and maximizing growth potential. The decentralized divisions utilize this framework to focus on the best market growth opportunities, top products, and customers, leading to above-market organic growth. This approach has also significantly improved on-time delivery rates across the company, routinely achieving 80% to 95% in most businesses, enabling faster customer fulfillment.

Growth-Biased Portfolio with Recurring Revenue

The company has intentionally built a growth-biased portfolio of precision technologies with reduced cyclicality. Approximately 60% of Nordson's portfolio generates recurring revenue from aftermarket parts, consumables, and services, providing stability. Furthermore, over 50% of the portfolio is now concentrated in high-growth end markets such as semiconductor, electronics, and medical, with the remaining exposures in more stable GDP-plus markets, underpinning confidence in future growth aspirations.

Balanced Capital Allocation Strategy

Nordson maintains a balanced capital allocation approach, fueled by its strong free cash flow generation. Year-to-date, the company has invested $40 million in capital projects to support current and future organic growth opportunities. Concurrently, it has returned capital to shareholders, with $137 million in dividends paid and $159 million in shares repurchased, all while reducing net debt and improving its leverage ratio to 1.7x, providing significant flexibility for strategic deployment.

Disciplined M&A Approach with Healthy Pipeline

M&A remains an important component of Nordson's growth algorithm, with a healthy pipeline of opportunities continuously being pursued. The company emphasizes discipline, ensuring potential acquisitions meet stringent strategic criteria, including attractive end market niches, differentiated technologies, and alignment with its growth-focused portfolio. Financial criteria, such as above-market growth, Nordson-like margins, and returns exceeding the cost of capital, are also critical for deployment of cash.

Industrial Precision Solutions (IPS) Stability and Emerging Applications

The IPS segment, representing approximately 50% of the company and valued between $1 billion and $1.4 billion, achieved 3% organic growth in Q3, aligning with its long-term goal. While margins remained strong at 35% of sales, the focus is on maximizing growth potential and maintaining margin performance amidst inflationary pressures. The business actively seeks new applications and pivots to end market niches, with early-stage opportunities identified in battery, solar, defense, and data center build-out applications.

Advanced Technology Solutions (ATS) Cycle Durability and Future Opportunities

The ATS segment delivered an all-time record Q3 with 30% organic growth, driven by both dispense and test and inspection businesses. Management believes the cycle still has room, expecting to build off this peak into FY27 at a mid-single-digit growth rate. A significant future opportunity lies in North American chip manufacturing infrastructure investments, which have not yet materially impacted Nordson's orders, suggesting further upside potential.

Medical and Fluid Solutions (MFS) Accelerating Growth

The MFS segment achieved 11% organic growth in Q3, exceeding its long-term target of 6-7%. This broad-based growth was driven by engineered fluid solutions, medical product lines, and electronics-based demand within the EFD business. Medical component demand is normalizing towards mid-single-digit growth, supported by strong order boards and pipeline activity, indicating a positive trajectory for the segment.

AI-generated summary of the company's earnings call. Not investment advice.